Sign in

CIK 0001725160

  • Non-accelerated filer
  • Smaller reporting company

Zentalis Pharmaceuticals, Inc.

Sign in to watch
Ticker
ZNTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
823607803
Phone
+1 858-263-4333
Business address
10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
Former names
Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
  1. 4 Grant or award Director acquired 260,192 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 3 Insider Initial Statement of Ownership
  4. 3 Insider Initial Statement of Ownership
  5. 4 Planned sale Principal Accounting Officer sold 1,603 shares at $3.18 ($5,098)
  6. 4 Grant or award Director acquired 41,581 shares (grant or award)
  7. 4 Grant or award Director acquired 41,581 shares (grant or award)
  8. 4 Grant or award Director acquired 48,429 shares (grant or award)
  9. 4 Open-market sale President, Interim CFO sold 9,597 shares at $11.98 ($114,972)
  10. 4 Grant or award Director acquired 72,481 shares (grant or award)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Open-market sale Chief Medical Officer sold 3,356 shares at $12.62 ($42,353)
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale Chief Financial Officer sold 2,573 shares at $11.44 ($29,435)
  15. 4 Open-market sale President sold 1,173 shares at $11.44 ($13,419)
  16. 4 Grant or award Chief Medical Officer acquired 337,500 shares (grant or award)
  17. 4 Open-market sale Chief Scientific Officer sold 1,585 shares at $11.54 ($18,291)
  18. 4 Open-market sale Chief Legal Officer sold 3,310 shares at $11.54 ($38,197)
  19. 4 Open-market sale President sold 11,552 shares at $11.54 ($133,310)
  20. 4 Open-market sale Chief Financial Officer sold 8,669 shares at $11.54 ($100,040)

Page 3 of 13 · 252 filings